Latest Articles
Quanta Therapeutics Presents Positive Phase 1 Data for QTX3034, an Oral G12D-Preferring Multi-KRAS Inhibitor, in Patients with Advanced Solid Tumors - The Manila Times
Quanta Therapeutics Presents Positive Phase 1 Data for QTX3034, an Oral G12D-Preferring Multi-KRAS Inhibitor, in Patients with Advanced Solid Tumors The Manila Times
Published: Oct. 24, 2025, 3:57 p.m.
Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer - BioSpace
Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer BioSpace
Published: Oct. 21, 2025, 5:15 a.m.
Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer - The AI Journal
Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer The AI Journal
Published: Oct. 20, 2025, 9:33 p.m.
Faeth Therapeutics: $25 Million Raised To Advance PIKTOR Phase 2 Trial Following 80% Response Rate In Endometrial Cancer - Pulse 2.0
Faeth Therapeutics: $25 Million Raised To Advance PIKTOR Phase 2 Trial Following 80% Response Rate In Endometrial Cancer Pulse 2.0
Published: Oct. 20, 2025, 3:54 p.m.
Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in E - PharmiWeb.com
Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in E PharmiWeb.com
Published: Oct. 20, 2025, 3:02 p.m.
Faeth Therapeutics Raises $25 Million, Reports Phase 2 Results in Ovarian and Endometrial Cancer - Femtech Insider
Faeth Therapeutics Raises $25 Million, Reports Phase 2 Results in Ovarian and Endometrial Cancer Femtech Insider
Published: Oct. 20, 2025, 2:27 p.m.
Faeth Therapeutics’ $92 Million Total Funding Powers PIKTOR Phase 2 - citybiz
Faeth Therapeutics’ $92 Million Total Funding Powers PIKTOR Phase 2 citybiz
Published: Oct. 20, 2025, 1:40 p.m.
Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer - Business Wire
Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer Business Wire
Published: Oct. 20, 2025, noon
Knight Therapeutics Announces Relaunch of MYFEMBREE® in Canada - GlobeNewswire
Knight Therapeutics Announces Relaunch of MYFEMBREE® in Canada GlobeNewswire
Published: Oct. 7, 2025, 9:08 p.m.
Nanoceria as Next-Generation Immunotherapeutics: Applications in Chronic Inflammation, Cancer, and Tissue Repair.
The immune system is crucial in protecting against disease, but it can also contribute to chronic illnesses when it malfunctions, with different conditions involving either inflammation or immune suppression. Current …
Published: Oct. 4, 2025, midnight
Link copied to clipboard!